Kidney removal with or without lymph node removal for high risk kidney cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study is for people with high-risk kidney cancer who are having their whole kidney removed. It compares surgery alone versus surgery plus removing lymph nodes from the tumor area to see if removing the nodes helps control the cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are scheduled for surgery to remove your entire kidney (radical nephrectomy).
- Your kidney cancer is considered high risk (for example, it's stage T3 or T4, or has spread to nearby lymph nodes, or you have had treatment to wipe out all visible metastatic spots).
- You have at least one visible tumor that can be measured on scans (RECIST v1.1).
- You are in good general health (ECOG 0 or 1) and your organs (bone marrow, kidneys, liver) are working well enough for surgery.
- You have not received any prior cancer therapy for this kidney cancer (like radiation, chemo, or targeted pills).
- You do not have another active cancer, a serious autoimmune disease, a recent blood clot or bleeding issue, or active infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This research study looks at the biology of kidney cancer that has spread to lymph nodes)Skip and tests tumor tissue to find which drugs might work best. By studying the tumor's genes and proteins, doctors hope to find more personalized treatment options for people with this condition.
This trial compares removing the kidney and ureter alone versus also removing nearby lymph nodes for high-risk upper tract urothelial cancer. It aims to see if the extra step helps improve outcomes.
This trial tests whether adding radiation therapy after surgery that removes only part of the ureter or the entire kidney and ureter helps prevent cancer from coming back in patients who have high-risk features like aggressive cell type or deep tumor invasion.
This study looks at whether removing nearby lymph nodes during standard kidney/ureter removal surgery helps people with upper tract urothelial carcinoma. You will be placed into one of two groups – one gets the usual surgery alone, the other gets surgery plus lymph node removal.
This trial tests a combination of three drugs—an immunotherapy (pembrolizumab) and two targeted therapies (belzutifan and lenvatinib)—given before surgery for high-risk kidney cancer. The goal is to see if this combination can shrink the tumor and improve outcomes after surgery.
This trial studies whether removing the kidney tumor with “deferred cytoreductive nephrectomy” (surgery at a later time) works best for people whose metastatic kidney cancer is already present. It compares a standard treatment approach using either immunotherapy (nivolumab/ipilimumab) or a targeted pill plus immunotherapy (TKI/IO), with planned surgery afterward.
Hear when a new Renal Cell Carcinoma (Kidney Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.